pravastatin has been researched along with enalapril in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 9 (52.94) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Coelho, OR; Mansur, AP; Nicolau, JC; Ramires, JA; Spósito, AC | 1 |
| Baiano, A; de Cristofaro, A; Del Forno, D; Giallauria, F; Paragliola, T; Rossi, M; Vigorito, C | 1 |
| Bayraktutan, U; Campbell, M; Mahadevan, VS; McKeown, PP | 1 |
| Komatsu, T; Kunugida, F; Nakamura, M; Orii, M; Ozawa, M; Sato, Y; Tachibana, H | 1 |
| Chang, YW; Cheng, HT; Liao, MT; Lin, WC; Lin, YH; Tsai, IJ; Tsau, YK | 1 |
| Medvedev, IN; Skoriatina, IA | 1 |
2 review(s) available for pravastatin and enalapril
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for pravastatin and enalapril
| Article | Year |
|---|---|
Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril).
Topics: Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Blood Pressure; Drug Interactions; Enalapril; Female; Heart Rate; Humans; Hypercholesterolemia; Hypertension; Lisinopril; Lovastatin; Male; Middle Aged; Pravastatin | 1999 |
14 other study(ies) available for pravastatin and enalapril
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
[Cardiac rehabilitation in a HIV-patient treated with protease inhibitors].
Topics: Adult; Aspirin; Carbazoles; Carvedilol; Cholesterol; Coronary Angiography; Diet Therapy; Drug Therapy, Combination; Enalapril; Exercise Therapy; HIV Infections; Humans; Male; Myocardial Infarction; Nitrates; Pravastatin; Propanolamines; Protease Inhibitors; Treatment Outcome; Triglycerides | 2003 |
Internal mammary artery smooth muscle cells resist migration and possess high antioxidant capacity.
Topics: 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; Amides; Angiotensin-Converting Enzyme Inhibitors; Antioxidants; Cells, Cultured; Chemotaxis; Coronary Vessels; Enalapril; Farnesyltranstransferase; Free Radical Scavengers; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Intracellular Signaling Peptides and Proteins; Lipoproteins, LDL; Losartan; Mammary Arteries; Metalloporphyrins; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Oxidative Stress; Pravastatin; Protein Serine-Threonine Kinases; Pyridines; Receptors, Oxidized LDL; rho-Associated Kinases | 2006 |
Long-term efficacy of upstream therapy using angiotensin-converting enzyme inhibitors and statins in combination with antiarrhythmic agents for the treatment of paroxysmal atrial fibrillation.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Drug Administration Schedule; Drug Therapy, Combination; Enalapril; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Retrospective Studies; Treatment Outcome | 2009 |
A rare cause of childhood-onset nephrotic syndrome: lipoprotein glomerulopathy.
Topics: Age of Onset; Anti-Inflammatory Agents; Antihypertensive Agents; Apolipoprotein E2; Child; Enalapril; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Methylprednisolone; Mutation; Nephrotic Syndrome; Pravastatin | 2012 |
[Erythrocyte aggregation in patients with arterial hypertension and dyslipidemia treated with pravastatin].
Topics: Anticholesteremic Agents; Antihypertensive Agents; Biological Availability; Drug Monitoring; Dyslipidemias; Enalapril; Erythrocyte Aggregation; Erythrocyte Membrane; Erythrocytes; Female; Humans; Hypertension; Lipid Peroxidation; Male; Middle Aged; Pravastatin; Severity of Illness Index; Treatment Outcome | 2014 |